Cellular Biomedicine Group Inc (CBMG):企業の財務・戦略的SWOT分析

◆英語タイトル:Cellular Biomedicine Group Inc (CBMG) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH451369FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥88,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥133,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cellular Biomedicine Group Inc (CBMG) is a clinical stage biopharmaceutical firm that develops biomedicine, immunotherapy products for cancer and stem cell therapies to address patient specific medical conditions. The firm’s products comprise clinical treatment protocols for the treatment of knee osteoarthritis, cancer, asthma and chronic obstructive pulmonary diseases. It offers treatment protocol services such as orthopaedic diseases including osteoarthritis and tissue damage; and other indications. CBMG utilizes proprietary cell based technologies to produce raw material, manufacture cells, and conduct cell banking and distribution. The firm has operations in Hong Kong, China and the US. CBMG is headquartered in Cupertino, California, the US.

Cellular Biomedicine Group Inc Key Recent Developments

Feb 19,2021: 14:55 ET Cellular Biomedicine Group, Inc. Announces Completion of Merger Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”) today announced the completion of the merger (the “Merger”) of the Company…
Feb 08,2021: Cellular Biomedicine Group, Inc. Stockholders Approve Merger
Nov 09,2020: Cellular Biomedicine Group reports Q3 2020 financial results and business highlights
Aug 12,2020: Cellular Biomedicine Group (CBMG) reports Q2, H1 2020 financial results and business highlights
Jul 13,2020: Cellular Biomedicine Group (CBMG) hosts R&D showcase and provides updates to clinical programs

This comprehensive SWOT profile of Cellular Biomedicine Group Inc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Cellular Biomedicine Group Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Cellular Biomedicine Group Inc – Key Information
Cellular Biomedicine Group Inc – Overview
Cellular Biomedicine Group Inc – Key Employees
Cellular Biomedicine Group Inc – Key Employee Biographies
Cellular Biomedicine Group Inc – Key Operational Heads
Cellular Biomedicine Group Inc – Major Products and Services
Cellular Biomedicine Group Inc – History
Cellular Biomedicine Group Inc – Company Statement
Cellular Biomedicine Group Inc – Locations And Subsidiaries
Cellular Biomedicine Group Inc
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Cellular Biomedicine Group Inc – Business Description
Cellular Biomedicine Group Inc – Corporate Strategy
Cellular Biomedicine Group Inc – SWOT Analysis
SWOT Analysis – Overview
Cellular Biomedicine Group Inc – Strengths
Cellular Biomedicine Group Inc – Weaknesses
Cellular Biomedicine Group Inc – Opportunities
Cellular Biomedicine Group Inc – Threats
Cellular Biomedicine Group Inc – Key Competitors

Section 3 – Company Financial Performance Charts

Cellular Biomedicine Group Inc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Cellular Biomedicine Group Inc, Key Information
Cellular Biomedicine Group Inc, Key Ratios
Cellular Biomedicine Group Inc, Share Data
Cellular Biomedicine Group Inc, Major Products and Services
Cellular Biomedicine Group Inc, History
Cellular Biomedicine Group Inc, Key Employees
Cellular Biomedicine Group Inc, Key Employee Biographies
Cellular Biomedicine Group Inc, Key Operational Heads
Cellular Biomedicine Group Inc, Other Locations
Cellular Biomedicine Group Inc, Subsidiaries
Cellular Biomedicine Group Inc, Key Competitors
Cellular Biomedicine Group Inc, SWOT Analysis
Cellular Biomedicine Group Inc, Ratios based on current share price
Cellular Biomedicine Group Inc, Annual Ratios
Cellular Biomedicine Group Inc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Cellular Biomedicine Group Inc (CBMG):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • The Scripps Research Institute-医療機器分野:企業M&A・提携分析
    Summary The Scripps Research Institute (TSRI) is a research and educational organization that conducts research in the areas of neurosciences, cardiovascular diseases, immunology, autoimmune diseases, chemistry, molecular and cellular biology, virology and synthetic vaccine development. The institut …
  • SMRT Corporation Ltd.:企業の戦略・SWOT・財務情報
    SMRT Corporation Ltd. - Strategy, SWOT and Corporate Finance Report Summary SMRT Corporation Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Pancontinental Oil & Gas NL (PCL):企業の財務・戦略的SWOT分析
    Summary Pancontinental Oil & Gas NL (Pancontinental) is an oil and gas exploration and production company. The company carries out acquisition, exploration and development of conventional oil and gas properties. The company offers projects such as Namibia Walvis Basin EL 0037, Kenya Lamu Basin L6, T …
  • Aareal Bank AG:企業の戦略・SWOT・財務情報
    Aareal Bank AG - Strategy, SWOT and Corporate Finance Report Summary Aareal Bank AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Pan-Provincial Vaccine Enterprise Inc-製薬・医療分野:企業M&A・提携分析
    Summary Pan-Provincial Vaccine Enterprise Inc (PREVENT) is a national vaccine commercialization consortium that specializes in research and development of vaccines for infectious diseases. The institute develops vaccines for infectious disease, group A streptococcus vaccine, chlamydia vaccine, influ …
  • NuVascular Technologies Inc:企業の製品パイプライン分析2018
    Summary NuVascular Technologies Inc (NuVascular Technologies) is a developer of medical devices for the treatment of patients suffering from end-stage renal diseases. The company offers hemodialysis access grafts, arteriovenous suture, central venous catheter cuffs, drug-eluting vessel wrap, drug-el …
  • Nationwide Mutual Insurance Company:企業の戦略・SWOT・財務情報
    Nationwide Mutual Insurance Company - Strategy, SWOT and Corporate Finance Report Summary Nationwide Mutual Insurance Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Corium International Inc (CORI):企業の製品パイプライン分析2018
    Summary Corium International Inc (Corium) is a commercial-stage biopharmaceutical company that produces and develops central nervous system pharmaceutical products. The company develops transdermal healthcare products with the help of Corplex technology platform using small molecules. Its products i …
  • Hino Motors Ltd (7205):企業の財務・戦略的SWOT分析
    Hino Motors Ltd (7205) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • AISIN SEIKI Co., Ltd.:企業の戦略・SWOT・財務情報
    AISIN SEIKI Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary AISIN SEIKI Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • AdAlta Ltd (1AD):製薬・医療:M&Aディール及び事業提携情報
    Summary AdAlta Ltd (AdAlta), formerly AdAlta Pty Ltd, is a biotechnology company that discovers and develops new class of protein therapeutics for wide range of human diseases. The company's lead i-body candidate, AD-114, is being developed for the treatment of idiopathic pulmonary fibrosis and othe …
  • The New Zealand Refining Co Ltd (NZR):石油・ガス:M&Aディール及び事業提携情報
    Summary The New Zealand Refining Co Ltd. (Refining NZ) is an oil refining company that refines and distributes oil products. It operates an oil refinery at Marsden Point in Whangarei, New Zealand. The company processes crude oil types imported from offshore markets and produces refined petroleum pro …
  • Deutsche Bahn AG:企業の戦略・SWOT・財務情報
    Deutsche Bahn AG - Strategy, SWOT and Corporate Finance Report Summary Deutsche Bahn AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Delta Corporation Limited:企業の戦略・SWOT・財務情報
    Delta Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary Delta Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Sensorion SA (ALSEN):企業の財務・戦略的SWOT分析
    Summary Sensorion SA (Sensorion) is a biopharmaceutical company that develops therapies. The company provides treatments for vestibular and cochlear pathologies. It develops drug candidates through its technology platform for the treatment of various therapeutic areas including vestibular neuritis, …
  • Wolters Kluwer N.V. (WKL):企業の財務・戦略的SWOT分析
    Wolters Kluwer N.V. (WKL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • The Royal Bank of Scotland Group Plc:企業のM&A・事業提携・投資動向
    The Royal Bank of Scotland Group Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's The Royal Bank of Scotland Group Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports …
  • Advanced Accelerator Applications SA:医療機器:M&Aディール及び事業提携情報
    Summary Advanced Accelerator Applications SA (AAA), a Novartis company, is engaged in developing, producing and commercializing diagnostic and therapeutic molecular nuclear medicine products. The company’s lead product candidate comprises Lutathera, NETSPOT, SOMAKIT TOC, Gluscan, Gluscan 500, Barnas …
  • Phatra Leasing Public Company Limited (PL):企業の財務・戦略的SWOT分析
    Phatra Leasing Public Company Limited (PL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • Kina Petroleum Ltd (KPL)-石油・ガス分野:企業M&A・提携分析
    Summary Kina Petroleum Limited (KPL) is an upstream oil and gas company that focuses on exploration, development and production activities. It has operations in Papua New Guinea (PNG) and Australia. The company focuses on participating in highly prospective oil and gas acreage positions near to prov …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆